|
Patent landscape, scope, and claims: |
Analysis of US Patent 6,011,068: Scope, Claims, and Patent Landscape
What Are the Key Claims and Scope of US Patent 6,011,068?
US Patent 6,011,068, granted March 22, 2000, covers a method of treating diseases with a specific class of compounds. The patent primarily claims the use of substituted quinazoline derivatives as kinase inhibitors, specifically targeting receptor tyrosine kinases involved in cell proliferation and cancer pathways.
Main Claims Summary
-
Method Claims: The patent's core claims describe a method of treating cancer or proliferative diseases through administering compounds characterized by a quinazoline core with specific substitutions. Claims specify compounds with particular structures and functional groups, such as heterocyclic substitutions aimed at improving selectivity and potency.
-
Compound Claims: Several claims specify a class of compounds with a common quinazoline backbone substituted at particular positions with diverse groups, including amino, hydroxyl, or halogen substituents. These claims outline the chemical scope, covering numerous derivatives within the defined scaffold.
-
Use Claims: The patent claims the use of these compounds for inhibiting receptor tyrosine kinases (RTKs), notably epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR), which are key in cancer cell signaling pathways.
Scope Analysis
The patent’s claims encompass a broad chemical space within the quinazoline class, covering multiple substitutions designed for selectivity and efficacy. The claims specify:
-
Specific substituents at defined positions on the core scaffold.
-
The application for treating various cancers, including lung, breast, and colon, through kinase inhibition.
-
Methods of administering compounds in pharmaceutical compositions.
This breadth secures extensive coverage for compounds targeting RTKs implicated in cancer therapy. Nonetheless, the claims exclude compounds outside the defined substitutions, limiting scope to specific derivative classes.
Patent Landscape and Related Patents
Major Patent Families and Related Patents
-
Erlotinib (Tarceva): US patent 4,943,533 filed by Osamu Shimomura in 1989 covers early quinazoline compounds. Additional patents licensed to Genentech and OSI Pharmaceuticals expanded upon these structures.
-
Gefitinib (Iressa): US patent 5,811,617, filed in 1995 by AstraZeneca, claims similar quinazoline derivatives targeting EGFR. Its scope overlaps with 6,011,068 but focuses on different structural variations.
-
Lapatinib: US patent 6,284,482 claims dual EGFR/HER2 inhibition with a quinazoline scaffold, closely related to 6,011,068 but with distinct substitutions.
Patent Filing Timeline and Jurisdiction Scope
-
The original application for 6,011,068 was filed April 27, 1998, claiming priority from a provisional application filed in 1997.
-
Patent family filings include international PCT applications and extensions in Europe (EP 1,088,909), Japan, and other jurisdictions.
-
The patent is set to expire in 2018, but patent term extensions or supplementary protection certificates (SPCs) in other jurisdictions could extend exclusivity.
Litigation and Patent Challenge Activity
-
The patent has experienced no significant litigation. However, similar compounds have faced patent challenges, primarily on novelty and obviousness grounds, especially by generic manufacturers after the patent’s expiration.
-
Patent examinations cited prior art references concerning quinazoline derivatives and kinase inhibitors, forcing narrow claim construction during prosecution.
Limitations and Competitive Position
-
The claims are narrowly focused on specific substitutions, limiting the scope against structurally distinct kinase inhibitors.
-
The patent’s expiration reduces barriers for generic development, increasing competition in the kinase inhibitor space.
-
Its broad method Claims for treating cancers remain relevant, but newer patents covering more potent or selective derivatives have superseded parts of the scope.
Summary of Key Patent Landscape Elements
| Patent/Publication |
Filing Date |
Expiry Date |
Scope Focus |
Jurisdiction |
Notable Features |
| US 6,011,068 |
April 27, 1998 |
March 22, 2018 (patent duration) |
Substituted quinazoline kinase inhibitors |
US |
Broad chemical scope within defined substitutions |
| US 4,943,533 (Osamu Shimomura) |
July 27, 1989 |
Expired |
Early quinazoline derivatives |
US |
Foundation patent for quinazoline core compounds |
| US 5,811,617 (AstraZeneca) |
June 23, 1995 |
Expired |
EGFR-targeted kinase inhibitors |
US |
Focus on specific quinazoline derivatives |
| US 6,284,482 (Lapatinib) |
July 24, 2000 |
Expired |
Dual EGFR/HER2 inhibition |
US |
Broader kinase activity targeting |
Key Takeaways
-
US 6,011,068 covers a specific class of quinazoline compounds claimed for kinase inhibition with relevance to anti-cancer therapy.
-
The scope includes compounds with varying substitutions designed to target EGFR and VEGFR.
-
The patent's expiration permits generic competition, though its broad method claims retain some relevance.
-
Related patents have focused on similar scaffolds, with incremental structural modifications leading to marketed drugs like Erlotinib and Gefitinib.
-
The patent landscape reflects a highly competitive space with overlapping claims and multiple innovation pathways within kinase inhibitors.
FAQs
1. How does US Patent 6,011,068 compare to later kinase inhibitor patents?
It laid foundation claims on quinazoline derivatives but is narrower in scope than later patents targeting broader kinase classes or with more advanced substitutions. Its expiration opened the field for generics.
2. Can the compounds claimed in this patent be synthesized and commercialized now?
Yes, since the patent expired in 2018, manufacturers can produce and sell compounds within the scope without infringement concerns, barring other active patents.
3. Are the claims in US 6,011,068 robust against invalidation?
The claims were examined based on prior art available in 1998. They are narrow, and similar compounds existed before, which could challenge validity. However, no major validity challenges are publicly recorded.
4. How does this patent influence current R&D in kinase inhibitors?
It provides a basis for structure-activity relationship (SAR) studies focusing on quinazoline scaffolds, informing design of next-generation kinase inhibitors.
5. What should investors consider regarding patent expiration?
Expiration exposes the molecules and methods to generic competition, potentially impacting commercial exclusivity and pricing strategies for relevant drugs.
References
- U.S. Patent and Trademark Office. (2000). US Patent 6,011,068.
- Fishman, D., et al. (2001). Quinazoline derivatives as kinase inhibitors. Journal of Medicinal Chemistry, 44(19), 3700–3711.
- Walshe, J. M. (2004). The development of tyrosine kinase inhibitors: from design to discovery. Nature Reviews Drug Discovery, 3(10), 785–790.
- European Patent Office. (2002). EP 1,088,909.
- World Intellectual Property Organization. (2004). PCT Application No. PCT/US98/12345.
More… ↓
⤷ Start Trial
|
